NasdaqGS:SYREBiotechs
A Look At Spyre Therapeutics (SYRE) Valuation After Its Large Capital Raise And Fresh Analyst Coverage
Spyre Therapeutics (SYRE) recently closed an underwritten public offering that raised about US$463.5 million. This provides the company with additional capital to fund its inflammatory and rheumatic disease programs and has drawn fresh attention from Wall Street coverage.
See our latest analysis for Spyre Therapeutics.
The stock has been volatile around these announcements, with a 1-day share price return decline of 6.76% and a 7-day share price return decline of 3.45%. However, a 30-day...